<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MELPHALAN</span><br/>(mel'fa-lan)<br/><span class="topboxtradename">Alkeran, </span><span class="topboxtradename">L-Pam, </span><span class="topboxtradename">Phenylalanine Mustard, </span><span class="topboxtradename">Alkeran IV<br/></span><b>Classifications:</b> <span class="classification">antineoplastic</span>; <span class="classification">alkylating agent</span><br/><b>Prototype: </b>Cyclophosphamide<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2 mg tablets; 50 mg powder for injection</p>
<h1><a name="action">Actions</a></h1>
<p>Nitrogen mustard chemically and pharmacologically related to mechlorethamine. Forms a highly reactive carbonium ion which
         causes cross-linking and abnormal base-pairing in DNA thereby interfering with DNA replication as well as RNA and protein
         synthesis.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Strong immunosuppressive and myelosuppressive effects but, unlike mechlorethamine, lacks vesicant properties. Carcinogenic
         potential suspected.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Chiefly for palliative treatment of multiple myeloma. Also many other neoplasms, including Hodgkin's disease and carcinomas
         of breast and ovary.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Polycythemia vera.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Lactation. Safety during pregnancy (category D) or in men and women of childbearing age is not established.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Recent treatment with other chemotherapeutic agents; concurrent administration with radiation therapy; severe anemia, neutropenia,
         or thrombocytopenia, Impaired kidney function.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Multiple Myeloma</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 6 mg/d for 23 wk, drug then withdrawn for 45 wk,  restart at 2 mg/d when WBC and platelet counts start to rise <span class="rdroute">IV</span> 16 mg/m<sup>2</sup> over 15 min q2wk for 4 doses<br/><br/><span class="indicationtitle">Epithelial Ovarian Cancer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 0.2 mg/kg/d in divided doses for 5 d as single course, may repeat course q45 wk, depending on hematologic tolerance<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with meals to reduce nausea and vomiting. An antiemetic may be ordered.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span> Reconstitute melphalan powder by <b> <small>RAPIDLY</small> </b> injecting 10 mL of the provided diluent into the vial to yield 5 mg/mL. Shake vigorously until clear. Immediately dilute
                  further with NS to a concentration of 0.45 mg/mL or less. Note: 45 mg in 100 mL yields 0.45 mg/mL. Do not refrigerate reconstituted
                  solution prior to infusion.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> IV Infusion:</span>  Give over <img src="../images/special/greaterorequal.gif"/>15 min. Administration <b> <small>MUST</small> </b> be completed within 60 min of reconstitution of drug because both reconstituted and diluted solutions are unstable.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Y-site:</span> <b> Amphotericin B,</b> <b>chlorpromazine.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store at 15°30° C (59°86° F) in light-resistant, airtight containers.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Hematologic:</span> <span class="speceff-life">Leukopenia, agranulocytosis, thrombocytopenia</span>, anemia, acute nonlymphatic leukemia. <span class="typehead">Body as a Whole:</span> Uremia, angioneurotic peripheral edema. <span class="typehead"> GI:</span> Nausea, vomiting, stomatitis. <span class="typehead">Skin:</span> Temporary alopecia. <span class="typehead">Respiratory:</span> Pulmonary fibrosis. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span>  Increases risk of nephrotoxicity with <b>cyclosporine.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Incompletely and variably absorbed from GI tract. <span class="typehead">Peak:</span> 2 h. <span class="typehead">Distribution:</span> Widely distributed to all tissues. <span class="typehead">Metabolism:</span>  Metabolized by spontaneous hydrolysis in plasma. <span class="typehead">Elimination:</span> 2550% excreted in feces. <span class="typehead">Half-Life:</span> 1.5 h; 2530% excreted in urine. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor WBC and platelet counts 23 times/wk during dosage adjustment period; determine WBC each week for
            68 wk during maintenance therapy. Monitor serum uric acid levels.
         </li>
<li>Monitor laboratory reports to anticipate leukopenic and thrombocytopenic periods.</li>
<li>A degree of myelosuppression is maintained during therapy so as to keep leukocyte count in range of 30003500/mm<sup>3</sup>.
         </li>
<li>Assess for flank and joint pains that may signal onset of hyperuricemia.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Be alert to onset of fever, profound weakness, chills, tachycardia, cough, sore throat, changes in kidney function, or prolonged
            infections and report to physician.
         </li>
<li>Understand that reversible hair loss is an expected adverse effect.</li>
<li>Do not breast feed while using this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>